LAURAS LABS

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs

with SL at 330 , one can go for target mentioned in chart

Market Cap
₹ 20,407 Cr.

Stock P/E
25.8

Book Value
₹ 70.5

Dividend Yield
0.53 %

ROCE
23.4 %

ROE
24.6 %

Face Value
₹ 2.00

Promoter holding
27.3 %

EPS last year
₹ 14.0

EPS latest quarter
₹ 4.23

Debt
₹ 1,925 Cr.

Pledged percentage
0.04 %

Net CF
₹ 1.55 Cr.

Price to Cash Flow
24.8

Free Cash Flow
₹ 61.6 Cr.

Debt to equity
0.51

Volume
1,195,742

OPM last year
27.3 %

OPM 5Year
25.0 %

Reserves
₹ 3,679 Cr.

Price to book value
5.38

Int Coverage
10.3

PEG Ratio
0.85